Pharmacogenomics is the branch of biotechnology dealing with genomic information to learn the effects and dosage of drugs on people, or in a simpler sense, it is the study of how differences in people’s genetics affect drug response. According to research, the pharmacogenomics market was valued at 7,169.74 million dollars in 2021 and is expected to reach 10,819.51 million dollars by 2027.
Each human genome is unique, just as each human being is unique. Therefore, each individual’s reaction to drugs is different. It is possible to incur costs, money, and adverse effects from the use of medications when a trial-and-error method is followed. And this high incidence rate of the adverse effect of medications is also promoting the adoption of pharmacogenomics in the global market. In recent years, researchers have focused on eliminating trial-and-error methods and studying human genomics to determine how drugs can best be prescribed at the individual’s level and based on their genetics.
The latest trend in pharmacogenomics is the provision of molecular diagnostic tools, which are used to optimize drug selection and dosage. With the rise of genome-wide sequencing or exome sequencing, genetic testing, and genomic services, improved usage of genetic information, drug selection, and dosage is possible.
With the rapid evolution of technologies, digital devices are developed to track user activity and capture digital biomarkers. Pharmacogenomics companies tap into advancing DNA technologies and digital health solutions to harness big data from genomics and revolutionize clinical trials and medical therapy.
In this edition, our aim is to provide readers with insights into the pharmacogenomics space.
Let us know your thoughts.
